REAL STORIES. REAL WORKERS. REAL STRENGTH.
Latest Stories
The US FDA has granted Bristol Myers Squibb an expanded indication for their drug Camzyos, allowing it to treat symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients weighing at least 30 kg. This development could have implications for American healthcare providers and patients seeking new treatment options.
SK Pharmteco is planning to invest over $200 million in the next five years to enhance its California and Texas facilities, focusing on expanding peptide capacity and creating 100 new jobs. This investment showcases a commitment to growth in the pharmaceutical industry, which contributes to American competitiveness and skilled work opportunities.
Bechtel’s manufacturing and technology business unit is assisting with the project, as reported in a job posting by the general contractor based in Reston, Virginia. This significant investment highlights the continued growth and development in the American manufacturing sector, which can have positive implications for workers and local communities.
Made Scientific has expanded its presence in the US by acquiring an 85,000ft² cell therapy manufacturing facility in Pennsylvania from National Resilience. This acquisition highlights the company’s commitment to investing in American industry and bolstering its production capabilities in the pharmaceutical sector.
Ultragenyx secures its second gene therapy approval, strengthening its market position with a new sellable voucher. In other industry news, Roche celebrates success in a blood cancer trial, while a cell therapy company focuses on cost-cutting measures. These developments offer valuable insights into the pharmaceutical sector, impacting American competitiveness and innovation in the healthcare industry.
The FDA’s new pilot program, part of ‘Operation Trialblazer,’ aims to speed up the process of bringing new medicines into human testing by partnering drugmakers with research institutions. This initiative could potentially benefit American pharmaceutical industry by accelerating drug development and testing processes.
The FDA has approved Isembyld, the first ‘muscle-targeted’ treatment for Spinal Muscular Atrophy (SMA). With analysts predicting it to be a future blockbuster, this drug has shown promising results in clinical testing by improving motor function in patients already on standard therapies. This approval could have a significant impact on the pharma industry and potentially benefit American patients and healthcare providers.
UniQure is now awaiting a decision from the FDA on its application for Huntington’s gene therapy, following a challenging year of navigating U.S. regulatory hurdles. This development in the pharma industry could have implications for American healthcare innovation and the treatment of genetic disorders.
Gilead Sciences has unveiled a new 182,000ft² research center at its Foster City headquarters in California, dedicated to advancing medicines for challenging diseases. This development underscores the company’s commitment to innovation and could have positive implications for American pharmaceutical industry and healthcare.
Genentech will invest $750 million to expand its Hillsboro, Oregon campus with a new drug device manufacturing facility, creating 250 manufacturing and 200 construction jobs, with operations expected by 2031.
News on U.S. pharmaceutical manufacturing, biotech, drug production, medical supply chains, facilities, investment, and the workers supporting American health innovation.
Top Stories
